A5018927191- Gastrointestinal motility and disorders
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Pancreatic and Hepatic Oncology Research
- Pain Management and Opioid Use
- Colorectal Cancer Treatments and Studies
- PI3K/AKT/mTOR signaling in cancer
- Gastroesophageal reflux and treatments
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Gastrointestinal Tumor Research and Treatment
- Thyroid Cancer Diagnosis and Treatment
- Diet and metabolism studies
- Esophageal Cancer Research and Treatment
- Cancer Treatment and Pharmacology
- Neutropenia and Cancer Infections
- Palliative Care and End-of-Life Issues
- Cell death mechanisms and regulation
- HER2/EGFR in Cancer Research
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Intestinal and Peritoneal Adhesions
- Social Media in Health Education
- Childhood Cancer Survivors' Quality of Life
- Ear and Head Tumors
Kishiwada City Hospital
2014-2025
Kindai University
2011-2024
Nara Medical University Hospital
2018-2024
Pfizer (Japan)
2009
BackgroundNivolumab is approved as an option for third- or later-line treatment of advanced gastric/gastroesophageal junction (G/GEJ) cancer in several countries after ATTRACTION-2. To further improve the therapeutic efficacy first-line therapy, exploration a nivolumab-chemotherapy combination warranted. In part 1 (phase II) ATTRACTION-4, safety and nivolumab combined with S-1 plus oxaliplatin (SOX) capecitabine (CapeOX) therapy unresectable recurrent human epidermal growth factor receptor 2...
Implementation of personalized medicine requires the accessibility tumor molecular profiling in order to allow prioritization appropriate targeted therapies for individual patients. Our aim was study role comprehensive genomic assays that may inform treatment recommendations patients with solid tumors.
This multicenter, prospective, observational cohort study assessed opioid induced constipation (OIC) in Japanese patients with cancer. Eligible had stable cancer and an ECOG PS of 0-2. OIC incidence based on the Rome IV diagnostic criteria was determined by patient diary entries during first 14 days therapy. The proportion calculated for each 1-week period overall 2-week period. Secondary measurements included Bowel Function Index (BFI) score (patient assessment administered physician),...
The combination of capecitabine and bevacizumab is a standard first-line chemotherapy regimen for vulnerable patients with unresectable colorectal cancer. However, the safety efficacy this in Japanese have not been sufficiently investigated. This phase II study included aged ≥76 years or those 65-75 who were unsuitable intensive chemotherapy. Capecitabine at 2000 mg/m2/day (days 1-14) plus 7.5 mg/kg (day 1) administered every 3 weeks. primary endpoint was progression-free survival. Secondary...
Immunotherapy has been shown to prolong survival in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) front-line use; however, subsequent systemic therapy not optimized. This study aimed evaluate safety efficacy cetuximab-containing chemotherapy after immunotherapy. We retrospectively analyzed patients with SCCHN who underwent regimens progression on Of 22 met inclusion criteria, 21 received paclitaxel cetuximab, 1 carboplatin fluorouracil cetuximab Nine achieved a...
Abstract Background Real-world evidence on the preference for and effectiveness of third- or later-line (3L +) monotherapy HER2-positive gastric cancer is limited in Japan. This study evaluated utility nivolumab, irinotecan, trifluridine/tipiracil (FTD/TPI) as 3L + treatment Japanese patients with gastric/gastroesophageal junction (G/GEJ) who were previously treated trastuzumab. Methods In this multicenter, retrospective, observational (20 centers), data eligible extracted from medical...
Background/Aim: This study aimed to seek clinical biomarkers of nivolumab monotherapy for advanced gastric cancer (AGC) which efficacy is limited. We focused on Glasgow Prognostic Score (GPS), reflects systemic inflammatory and nutritional status as well disease control by chemotherapy immediately before (DCBC). Patients Methods: AGC patients with measurable lesions who were treated in the third- or later-line included. DCBC was defined a best overall response complete (CR), partial...
Extension of metastatic lung tumors into the left atrium via pulmonary veins is rare. Here, we report first case Ewing sarcoma exhibiting such extension. A 31-year-old man with metastasis from presented a mass in lung, extending to through inferior vein. As patient was considered be at risk tumor embolism, excised surgically.
280 Background: Cisplatin (CDDP) plus fluoropyrimidine was the standard first-line treatment in patients with advanced esophageal squamous cell carcinoma (ESCC). FOLFOX is promising option especially ESCC intolerant to CDDP but there were limited data on efficacy and safety of FOLFOX. We conducted a multicenter prospective observational study for Japanese CDDP. Methods: Eligible participants had clinical stage IVB ESCC, measurable disease, Eastern Cooperative Oncology Group (ECOG)...
Abstract Background Constipation is a common side effect of opioid therapy. An observational study opioid-induced constipation (OIC) in Japanese patients with cancer (OIC-J) included 212 various tumor types. This post hoc analysis OIC-J evaluated subgroup gastrointestinal (GI) cancer. Methods Patients were aged ≥ 20 years, starting strong therapy, had an ECOG PS ≤ 2, and must have 3 bowel movements during the week before enrollment. OIC was for 2 weeks after initiation using Rome IV...
ContextMany patients who have cancer consider opioid-induced constipation (OIC) to be a burdensome side effect of opioid treatment.ObjectivesTo evaluate patient-reported outcomes in Japanese with pain and OIC.MethodsThis prospective observational study evaluated OIC incidence for two weeks after they initiated strong therapy. Rome IV diagnostic criteria, physician's diagnosis, spontaneous bowel movements, Bowel Function Index score, patients' daily self-assessments were used. Changes from...
Background Sunitinib is an oral multitargeted tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived receptors, as well other receptor types. We have performed a feasibility study to investigate the safety sunitinib in combination with pemetrexed for treatment advanced refractory solid tumors. Methods was administered once daily on continuous dosing (CDD) schedule (37.5 mg/day) or 2-weeks-on, 1-week-off (50 mg/day, Schedule 2/1) at 500 mg/m2 day 1 repeated...
To evaluate the opioid-induced constipation burden in subgroup of patients with lung cancer who participated observational Opioid-Induced Constipation Patients Cancer Pain Japan (OIC-J) study.
We report a case of conversion surgery for pancreatic ductal adenocarcinoma (PDAC) with synchronous distant metastases showing pathological complete response (pCR) after FOLFIRINOX therapy. A 46-year-old woman obstructive jaundice was referred to our hospital. CT scan revealed hypo-vascular mass in the head pancreas multiple para-aortic lymph nodes and Virchow's node swollen. The serum CA 19-9 level 71795.1 U/mL. result tumor biopsy from biliary stenotic site concordant adenocarcinoma. She...
e14630 Background: SU is an oral, multitargeted tyrosine kinase inhibitor of VEGFRs, PDGFRs, KIT, RET, FLT3, and CSR-1, shows antitumor activities in several types solid malignancies. Non-small-cell lung cancer (NSCLC) xenograft data indicate enhanced the activity Pem. This phase I study was designed to evaluate safety, tolerability, pharmacokinetics (PK) combination therapy with oral Pem for Japanese patients advanced ST. Methods: Pts ST refractory standard were randomly assigned receive...
Opioid-induced constipation (OIC) can limit the clinical benefit of opioid treatment. This post-hoc analysis evaluated association between Rome IV diagnostic criteria and other measures for OIC, including Bowel Function Index (BFI), correlation demographics OIC onset, impact on pain treatment, patient–healthcare professional (HCP) communication patient satisfaction. Patients recorded bowel habits in paper diaries 14 days following initiation. Study-specific questionnaires were used to...
277 Background: The real-world effectiveness of third- or later-line (3L+) therapies in patients (pts) with HER2-positive gastric cancer remains unknown. We report a multicenter, retrospective, observational study at 20 centers Japan to investigate the outcomes 3L+ therapy pts advanced gastric/gastroesophageal junction (G/GEJ) previously receiving trastuzumab (UMIN000040853). Methods: Pts aged ≥20 years G/GEJ who were treated and newly initiated on nivolumab, irinotecan,...